Baidu
map

Cell:邹伟平教授揭秘肿瘤免疫与化疗关系

2016-05-04 生物谷 生物谷

成纤维细胞会减少癌细胞内的铂含量,导致化疗药物抵抗   成纤维细胞释放的谷胱甘肽和半胱氨酸会促进癌细胞对铂的抵抗   T细胞可以改变成纤维细胞的谷胱甘肽和半胱氨酸代谢,削弱成纤维细胞介导的癌细胞对化疗药物的抵抗   成纤维细胞和CD8+T细胞共同左右了病人对化疗药物的应答     近日,来自美国密歇根大学的华人科学家邹伟平领导

成纤维细胞会减少癌细胞内的铂含量,导致化疗药物抵抗
 
成纤维细胞释放的谷胱甘肽和半胱氨酸会促进癌细胞对铂的抵抗
 
T细胞可以改变成纤维细胞的谷胱甘肽和半胱氨酸代谢,削弱成纤维细胞介导的癌细胞对化疗药物的抵抗
 
成纤维细胞和CD8+T细胞共同左右了病人对化疗药物的应答
 
 
近日,来自美国密歇根大学的华人科学家邹伟平领导的研究团队在国际学术期刊Cell上发表了一项最新研究进展,他们发现肿瘤微环境中的效应T细胞能够通过削弱基底层细胞介导的化疗抵抗增强化疗药物效果。
 
邹伟平教授是生命科学领域取得杰出成就的华人科学家,其专业领域涉及肿瘤、免疫、炎症以及转化医学,在肿瘤和机体免疫的相互作用研究及其应用方面取得了一系列重要成果。
 
效应T细胞和成纤维细胞是组成肿瘤微环境的两种主要细胞成分。肿瘤微环境被认为是导致癌细胞抵抗化疗药物的重要原因,但效应T细胞和成纤维细胞究竟如何影响化疗药物抵抗过程一直不清楚。
 
在这项最新研究中,研究人员发现成纤维细胞能够减少铂在卵巢癌细胞核内的积累,成为癌细胞抵抗铂类化疗药物的重要原因。与此同时他们还发现成纤维细胞释放的谷胱甘肽和半胱氨酸促进了癌细胞对化疗药物的抵抗。
 
效应T细胞也会影响癌细胞对化疗药物的应答,但是与成纤维细胞不同,CD8+ T细胞通过改变成纤维细胞内谷胱甘肽和半胱氨酸代谢过程削弱了癌细胞对化疗药物的抵抗。研究人员发现CD8+ T细胞产生的IFNγ能够上调γ-谷氨酰转移酶,并通过JAK/STAT1途径抑制胱氨酸和谷氨酸逆向协同转运蛋白的表达控制成纤维细胞内谷胱甘肽和半胱氨酸的产生。
 
除此之外,研究结果还表明,基底层成纤维细胞和CD8+ T细胞的出现分别与卵巢癌病人存活率呈现负相关和正相关关系。
 
这项研究揭示了肿瘤微环境中效应T细胞的一种作用机制:它们通过削弱基底层成纤维细胞介导的化疗药物抵抗增强肿瘤治疗效果。同时,该研究还提示把握化疗与免疫治疗之间的相互关系对于癌症治疗具有非常重要的意义。

原始出处:

Weimin Wang, Ilona Kryczek, Lubomír Dostál, Heng Lin, Lijun Tan, Lili Zhao, Fujia Lu, Shuang Wei, Tomasz Maj, Dongjun Peng, Gong He, Linda Vatan, Wojciech Szeliga, Rork Kuick, Jan Kotarski, Rafa? Tarkowski, Yali Dou, Ramandeep Rattan, Adnan Munkarah, J. Rebecca Liu10,correspondenceemail, Weiping Zou. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.DOI: http://dx.doi.org/10.1016/j.cell.2016.04.009

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959605, encodeId=a89d195960576, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 21 18:40:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869348, encodeId=d70f1869348af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 24 16:40:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85160, encodeId=e6668516047, content=现在医疗的趋势, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85161, encodeId=422685161b3, content=做研究也很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85162, encodeId=0ed9851625c, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85159, encodeId=e9208515924, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:39:00 CST 2016, time=2016-05-09, status=1, ipAttribution=)]
    2016-05-21 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959605, encodeId=a89d195960576, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 21 18:40:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869348, encodeId=d70f1869348af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 24 16:40:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85160, encodeId=e6668516047, content=现在医疗的趋势, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85161, encodeId=422685161b3, content=做研究也很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85162, encodeId=0ed9851625c, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85159, encodeId=e9208515924, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:39:00 CST 2016, time=2016-05-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959605, encodeId=a89d195960576, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 21 18:40:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869348, encodeId=d70f1869348af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 24 16:40:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85160, encodeId=e6668516047, content=现在医疗的趋势, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85161, encodeId=422685161b3, content=做研究也很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85162, encodeId=0ed9851625c, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85159, encodeId=e9208515924, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:39:00 CST 2016, time=2016-05-09, status=1, ipAttribution=)]
    2016-05-09 stead

    现在医疗的趋势

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1959605, encodeId=a89d195960576, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 21 18:40:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869348, encodeId=d70f1869348af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 24 16:40:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85160, encodeId=e6668516047, content=现在医疗的趋势, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85161, encodeId=422685161b3, content=做研究也很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85162, encodeId=0ed9851625c, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85159, encodeId=e9208515924, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:39:00 CST 2016, time=2016-05-09, status=1, ipAttribution=)]
    2016-05-09 stead

    做研究也很好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1959605, encodeId=a89d195960576, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 21 18:40:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869348, encodeId=d70f1869348af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 24 16:40:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85160, encodeId=e6668516047, content=现在医疗的趋势, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85161, encodeId=422685161b3, content=做研究也很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85162, encodeId=0ed9851625c, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85159, encodeId=e9208515924, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:39:00 CST 2016, time=2016-05-09, status=1, ipAttribution=)]
    2016-05-09 stead

    真的不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1959605, encodeId=a89d195960576, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 21 18:40:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869348, encodeId=d70f1869348af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 24 16:40:00 CST 2016, time=2016-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85160, encodeId=e6668516047, content=现在医疗的趋势, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85161, encodeId=422685161b3, content=做研究也很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85162, encodeId=0ed9851625c, content=真的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:40:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85159, encodeId=e9208515924, content=学习了,很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160509/IMG572FCF18A71237916.jpg, createdBy=d0861720708, createdName=stead, createdTime=Mon May 09 23:39:00 CST 2016, time=2016-05-09, status=1, ipAttribution=)]
    2016-05-09 stead

    学习了,很好的

    0

相关资讯

盘点:2016年4月21日Nature期刊精华

本周又有一期新的Nature期刊(2016年4月21日)发布,它有哪些精彩研究呢?让小编一一道来。 1. Nature:细菌群体CRISPR-Cas多样性有助限制病毒扩散 在一项新的研究中,来自英国埃克塞特大学等机构的研究人员证实宿主(如细菌)基因多样性通过限制寄生物(如病毒)进化而有助降低疾病扩散。相关研究结果于2016年4月13日在线发表在Nature期刊上,论文标题为“The

PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著,1/3患者达到5年生存

百时美PD-1抑制剂Opdivo近日在临床试验方面取得新进展,为这一万众瞩目的明星药物增添了新一抹亮色。百时美公司发布了两组数据,其中一组显示,使用Opdivo治疗晚期黑色素瘤的患者中,三分之一以上的患者达到了五年生存期。 更加值得注意的是,这34%生存期达到5年的黑色素瘤患者在服药之前几乎都已经被判“死刑”,在此之前没有一种药物能够阻止黑色素瘤转移。一般而言,IV期黑色素瘤患者的五年生存率

SITC 2015:聚焦国际肿瘤免疫治疗前沿趋势

2015年第30届癌症免疫治疗协会年会(SITC)于11月4日-8日在美国——马里兰州——国家港口召开; CAR-T细胞治疗现状:安全性及疗效 肿瘤免疫疗法的疗效评价 FDA加速免疫治疗审批程序 Public Accessto CBER 结论:1.新的治疗方法带来新的监管挑战; 2.个体化治疗(精准治疗)需要新的临床dev

CSCO 2015:肿瘤免疫治疗:肿瘤治疗的未来趋势

恶性肿瘤是目前全世界的主要死亡原因之一,已经成为严重危害人类生命健康、制约社会经济发展的一大类疾病。《2014年全球癌症报告》称2012年全球癌症患者和死亡病例都在令人不安地增加,新增癌症病例有近一半出现在亚洲,其中大部分在中国,中国新增癌症病例高居第一位。在肝、食道、胃和肺等4种恶性肿瘤中,中国新增病例和死亡人数均居世界首位。 在日前召开的第十八届全国临床肿瘤学大会暨 2015 年

Cell:微生物组和抗肿瘤免疫监视

微生物菌群在机体中的作用越来越受重视,不仅仅在肠道的消化功能中,在众多的功能中都可能起到关键作用,包括肿瘤。 微生物组对肿瘤的影响可能是全方位的,尤其是肿瘤的免疫监视策略的影响,至少包括如下几种方式: 1 抗肿瘤免疫反应是自身免疫力,被菌群深度影响; 2 菌群直接参与抗肿瘤免疫监视,也能通过全身性作用影响远端; 3 机制可能涉及三因素的交叉响应:菌群、能塑造T细胞角色的肿

分子分型时代,膀胱癌和乳腺癌竟然是一种疾病?

随着人类基因组的面纱逐渐被揭开,分子和基因逐渐取代细胞和组织成为癌症具体分型的依据。最近,北卡罗来纳大学教堂山分校的研究人员在JCI Insight杂志上发表的一项研究结果表明,膀胱癌的一种新亚型与某些类型乳腺癌的分子特征类似。 膀胱癌占美国所有新发癌症的5%左右,是男性第四大常见肿瘤,在女性中则发病率较低。预计在2016年,将有76960名美国人发现自己患上膀胱癌,大约16390名患者

Baidu
map
Baidu
map
Baidu
map